Avenue Therapeutics Stock Quote ATXI - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.54

Bid

3.43

Ask

3.65

Volume

61,257

3.40 Day's Range 3.65

3.21 52 Week Range 87.00

Market Cap

3.331M

Previous Close

3.45

Open

3.45

Last Trade

195

3.54

Last Trade Time

11:08:28

Financial Volume

$ 216,184

VWAP

3.5291

Average Volume (3m)

60,299

Shares Outstanding

940,986

Dividend Yield

PE Ratio

-0.31

Earnings Per Share (EPS)

-11.03

Revenue

Net Profit

-10.38M

Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain. Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.avenuetx.com

Headquarters

Dover, Delaware, USA

Founded

1970

Avenue Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATXI. The last closing price for Avenue Therapeutics was $3.45. Over the last year, Avenue Therapeutics shares have traded in a share price range of $ 3.21 to $ 87.00.

Avenue Therapeutics currently has 940,986 shares outstanding. The market capitalization of Avenue Therapeutics is $3.25 million. Avenue Therapeutics has a price to earnings ratio (PE ratio) of -0.31.

Form S-8 - Securities to be offered to employees in employee benefit plans

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Form 8-K - Current report

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.12	3.50877192982	3.42	3.76	3.32	33755	3.56191146	CS
4	-0.16	-4.32432432432	3.7	3.7999	3.21	29300	3.50074951	CS
12	-0.84	-19.1780821918	4.38	5.97	3.21	60299	4.0766899	CS
26	-7.065	-66.6195190948	10.605	15	3.21	989398	10.4532124	CS
52	-80.46	-95.7857142857	84	87	3.21	2026997	17.6331496	CS
156	-2347.71	-99.8494417863	2351.25	2351.25	3.21	1804195	350.75464584	CS
260	-6780.21	-99.9478164732	6783.75	14130	3.21	1147042	715.79947325	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF	20.10 (839.25%)	128.72k
SLRXSalarius Pharmaceuticals Inc	$ 5.04 (227.27%)	30.06M
RGCRegencell Bioscience Holdings Ltd	$ 10.64 (215.73%)	85.36k
ADILAdial Pharmaceuticals Inc	$ 1.6993 (60.31%)	137.59M
ATPCAgape ATP Corporation	$ 0.2273 (58.95%)	86.37M
JAGXJaguar Health Inc	$ 1.4999 (-64.87%)	9.15M
RNAZTransCode Therapeutics Inc	$ 0.30 (-62.15%)	5.11M
FLYEFly E Group Inc	$ 2.60 (-59.25%)	3.8M
MIRAMIRA Pharmaceuticals Inc	$ 2.43 (-51.50%)	17.96M
CMAXCareMax Inc	$ 3.22 (-37.96%)	6.67M
ADILAdial Pharmaceuticals Inc	$ 1.6993 (60.31%)	137.59M
ATPCAgape ATP Corporation	$ 0.2273 (58.95%)	86.37M
SLNASelina Hospitality PLC	$ 0.0251 (-32.16%)	75.38M
NVDANVIDIA Corporation	$ 123.15 (-0.32%)	64.8M
WRNTWarrantee Inc	$ 0.3061 (5.19%)	64.37M